| Enbrel (etanercept) / Pfizer, Amgen |
NCT00691106: A Multi-center Study to Evaluate the Safety of Etanercept in the Treatment of Lichen Planus |
|
|
| Active, not recruiting | 2 | 5 | US | etanercept | Wake Forest School of Medicine | Lichen Planus | 03/08 | 09/09 | | |
2014-001323-76: Study to evaluate the tolerability of a combination therapy consisting of GAD-alum (Diamyd®), etanercept and vitamin D in children and adolescents newly diagnosed with type 1 diabetes |
|
|
| Ongoing | 2 | 20 | Europe | Diamyd, Enbrel 25 mg pulver och vätska till injektionsvätska, lösning, D-vitamin, Olja ACO 80 IE per droppe, orala droppar, lösning, rhGAD65 formulated in alum (GAD-alum), Suspension for injection, Powder and solvent for solution for injection, Oral drops, Enbrel 25 mg pulver och vätska till injektionsvätska, lösning, D-vitamin, Olja ACO orala droppar, lösning | Linköping University, Linköping University, County Council, Östergötland, Diamyd | Newly diagnosed Type 1 diabetes (within 100 days), Newly Diagnosed Type 1 diabetes (within 100 days), Diseases [C] - Hormonal diseases [C19] | | | | |
2004-004914-18: A pilot multicentric study for the use of the anti-TNF alfa in patients with: 1) Fanconi Anemia with marrow failure with no bone marrow compatible donor 2) In patients with acquired aplastic anemia failing immunosuppression and with no bone marrow donor Studio pilota multicentrico per l\'uso di anti-tnf-alfa in pazienti con: 1) Anemia di Fanconi con insufficienza midollare senza un donatore di midollo osseo compatibile e 2) in pazienti con Aplasia Midollare Acquisita resistenti alla immunosoppressione e senza un donatore di midollo osseo. |
|
|
| Ongoing | 2 | 5 | Europe | NA, NA, ENBREL*SC 4FL 25MG+4SIR 1ML, ENBREL*SC 4FL 25MG+4SIR 1ML | ISTITUTO GIANNINA GASLINI | Marrow failure in patients refractary/non eligible to conventional treatments Insufficienza midollare in pazienti refrattari/non eleggibili ai trattamenti convenzionali di prima e seconda linea | | | | |
2008-006726-34: Anti-TNF monoclonal antibody to treat acute GvHD refractary to the first line therapy with steroids |
|
|
| Ongoing | 2 | 20 | Europe | ENBREL, ENBREL | ISTITUTO GIANNINA GASLINI | Anti-TNF monoclonal antibody to treat acute GvHD refractary to the first line therapy with steroids | | | | |
2009-015515-40: PREVENTION OF THE PROGRESSION OF VERY EARLY SYMPTOMSINTO ANKYLOSING SPONDYLITIS: A PLACEBO CONTROLLED TRIAL WITH ETANERCEPT |
|
|
| Ongoing | 2 | 80 | Europe | Enbrel, Enbrel | Wyeth Pharmaceuticals B.V. | The diagnosis of Ankylosing Spondylitis (AS) requires radiographically proven sacroiliitis.Inflammation on MRI is a prognostic factor for the development of AS. The aim is the decrease of inflammation on MRI of the SI joint and/or spine by giving them, a short period, anti-TNF therapy. The study is designed as a randomized, double-blind, placebo-controlled trial. After inclusion patients are randomly assigned to the etanercept- or placebo-arm of the study in a 1:1 ratio during 16 weeks. | | | | |
2015-002145-63: A study examining the effect of etanercept (Enbrel)on inflammation in the brain. |
|
|
| Ongoing | 2 | 46 | Europe | Enbrel, Not applicable, Enbrel, Enbrel | University of Southampton, European Union FP7 grant, Alzheimer's Society UK and Alzheimer Drug Discovery Foundation | Mild Cognitive impairment- due to Alzheimer\'s disease- intermediate likelihood | | | | |
NCT02464878: Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant |
|
|
| Completed | 2 | 2 | US | Alpha 1-Antitrypsin, Glassia, Islet Transplantation, Thymoglobulin, Antithymocyte Globulin, Basiliximab, Etanercept, Enbrel | Massachusetts General Hospital, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Iowa | Kidney Transplant, Type 1 Diabetes | 11/22 | 12/22 | | |
ACTRN12620001011976: A Prospective multicentre, phase 2b randomised controlled double-blind trial, to determine the safety and efficacy of perispinal etanercept on quality of life at 28 days post treatment |
|
|
| Terminated | 2 | 168 | | | The Florey Institute of Neuroscience and Mental Health, Stroke Foundation, Medical Research Future Fund | acute ischemic stroke, hemorrhagic stroke | | | | |
| Recruiting | 2 | 88 | US | Etanercept, Enbrel, Saline | Wayne State University, University of Miami, Michigan Ear Institute | Tinnitus, Noise Induced | 09/25 | 09/25 | | |
ChiCTR2300079203: A Single-arm, Open-label Clinical Study of Enbrelizumab Combined with Endostar and Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer |
|
|
| Recruiting | 2 | 25 | | Envafolimab combined with Endostar and concurrent chemoradiotherapy | Henan Provincial People's Hospital; Henan Provincial People's Hospital, Beijing Bethune Public Welfare Foundation | Locally advanced cervical cancer | | | | |
| Recruiting | 1/2 | 80 | | | Griffith University, Stroke Recovery Trial Fund, Stroke Recovery Trial Fund | Chronic Stroke | | | | |
2019-002186-36: Treatment of acute graft-versus-host disease after allogeneic stem cell transplantation with placenta derived decidua stroma cells (DSC) compared with best available treatment (BAT). |
|
|
| Ongoing | 1/2 | 56 | Europe | Decidua Stroma Cells, DSC, L01XE18, L04AA, L04AX03, L04AA06, L01XE10, L04AA10, L04AB01, L04AB02, Solution for injection/infusion, , Powder and solution for solution for injection, Tablet, Powder and solvent for dispersion for injection, Solution for blood fraction modification, Jakavi, Entyvio, Methotrexate, Cellcept, Afinitor, Rapamune, Enbrel, Remicade, Extracorporeal photophersis, Methoxalen | Uppsala University Hospital, Swedish Research Council | Steroid refractory acute GVHD Kortison refraktär akut GVHD, Acute graft-versus-host reaction after allogeneic stem cell transplantation not responding to steroid treatment. Akut transplantat-mot-värd reaktion som inte svarar på kortison behandling., Diseases [C] - Immune System Diseases [C20] | | | | |
ACTRN12620000912987: Clinical Trial of Perispinal Etanercept Treatment for Stroke patients to examine the effect on fatigue and muscle spasticity. |
|
|
| Completed | 1/2 | 80 | | | Griffith University, Griffith University | Stroke, Fatigue, Muscle Spasticity | | | | |
NCT04082910: Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells |
|
|
| Recruiting | 1/2 | 30 | RoW | Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents | Chinese PLA General Hospital | Solid Tumor, Hematological Malignancy | 12/22 | 12/23 | | |
| Not yet recruiting | 1/2 | 12 | NA | ToleraCell-001, ToleraCell-002, DFI-105, Etanercept, Tocilizumab, Sirolimus | Diabetes Free, Inc. | Diabetes Mellitus Type 2 - Insulin-Treated | 01/26 | 06/26 | | |
NCT03182426: Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM) |
|
|
| Completed | 1/2 | 22 | Canada | Plerixafor, Mozobil, Alemtuzumab, Lemtrada, Anakinra, Kineret, Etanercept, Enbrel, Liraglutide, Victoza | University of Alberta, Alberta Innovates Health Solutions | Diabetes Mellitus, Type 1 | 07/24 | 07/24 | | |
| Recruiting | 1/2 | 50 | Europe | Decidua Stroma Cells (DSC), Best available Treatment (BAT), ECP, Everolimus, Sirolimus, Etanercept, Vedolizumab, Ruxolitinib, Infliximab. | Mats Remberger, The Swedish Research Council | GVHD, Acute | 12/24 | 12/29 | | |
